Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Institutes of Health Clinical Center (CC)
Study ID
NCT00734890
Phase
PHASE1
Status
Completed

Conditions

  • Lung Cancer
  • Lymphoma
  • Lymphoproliferative Disorder
  • Small Intestine Cancer
  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • vandetanib — DRUG
  • laboratory biomarker analysis — OTHER
  • pharmacological study — OTHER

Study Details

RATIONALE: Vandetanib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab and vandetanib may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving vandetanib together with bevacizumab may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vandetanib and bevacizumab in treating patients with advanced solid tumors or lymphoma.

Key Dates

First listed
Aug 14, 2008
Start date
Mar 31, 2008
Status verified
Mar 2012
Primary completion
Jun 30, 2010
Completion
Feb 28, 2011

Study Design

Enrollment
18 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Maximum tolerated dose

Locations (1)

FacilityCityStateZIPSite coordinators
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral OfficeBethesdaMaryland20892-1182-

Find similar trials in Bethesda, MD

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office· Bethesda, MD

Related Studies